Abstract
There is considerable evidence that T-helper 2 (Th2) cells play a central role in the pathogenesis of allergic diseases such as bronchial asthma, hay fever or food allergy. The differentiation of naïve T cells into Th2 cells producing a specific pattern of cytokines is tightly controlled and regulated by transcription factors. Thus down-regulation of mRNAlevels of a single transcription factor leads to a “knock-down” of several mediators simultaneously, representing an advantage compared to earlier approaches involving down-regulation of one intercellular inflammatory mediator, which is unlikely to influence all pathophysiological aspects of the disease. We review the impact of specific and master transcription factors involved in Th2 cell commitment and evaluate approaches for the down-regulation of these proteins by degradation of their mRNA using nucleic-acid based technologies including antisense oligonucleotides, ribozymes, DNAzymes, decoys oligonucleotides and RNA interference.
Keywords: Nucleic-acid based technology, antisense, therapeutic tool, transcription factor, allergy, asthma
Current Pharmaceutical Design
Title: Treatment of Allergic Asthma by Targeting Transcription Factors Using Nucleic-Acid Based Technologies
Volume: 12 Issue: 25
Author(s): Serdar Sel, Wolfgang Henke, Alexander Dietrich, Udo Herz and Harald Renz
Affiliation:
Keywords: Nucleic-acid based technology, antisense, therapeutic tool, transcription factor, allergy, asthma
Abstract: There is considerable evidence that T-helper 2 (Th2) cells play a central role in the pathogenesis of allergic diseases such as bronchial asthma, hay fever or food allergy. The differentiation of naïve T cells into Th2 cells producing a specific pattern of cytokines is tightly controlled and regulated by transcription factors. Thus down-regulation of mRNAlevels of a single transcription factor leads to a “knock-down” of several mediators simultaneously, representing an advantage compared to earlier approaches involving down-regulation of one intercellular inflammatory mediator, which is unlikely to influence all pathophysiological aspects of the disease. We review the impact of specific and master transcription factors involved in Th2 cell commitment and evaluate approaches for the down-regulation of these proteins by degradation of their mRNA using nucleic-acid based technologies including antisense oligonucleotides, ribozymes, DNAzymes, decoys oligonucleotides and RNA interference.
Export Options
About this article
Cite this article as:
Sel Serdar, Henke Wolfgang, Dietrich Alexander, Herz Udo and Renz Harald, Treatment of Allergic Asthma by Targeting Transcription Factors Using Nucleic-Acid Based Technologies, Current Pharmaceutical Design 2006; 12 (25) . https://dx.doi.org/10.2174/138161206778194150
DOI https://dx.doi.org/10.2174/138161206778194150 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacogenetics and Anaesthesiology
Current Pharmacogenomics Subject Index to Volume 2
Current Drug Targets - Inflammation & Allergy Immunostimulatory Oligonucleotides
Recent Patents on Inflammation & Allergy Drug Discovery The Long and Winding Road to Convert an Antimicrobial Compound into an Antimicrobial Drug: An Overview from a Medicinal Chemistry Point of View
Current Organic Chemistry Current Status of Clinical Trials for Glioblastoma
Reviews on Recent Clinical Trials Evaluation of the Risk/Benefit Ratio of Old and New Anti-Inflammatory Drugs
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Role of Alpha1-Antitrypsin Deficiency in Respiratory Disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Optimal Sedation for the Ventilation of Critically Ill Patients
Current Respiratory Medicine Reviews Molecular Imprinting of Biologically Active Steroidal Systems
Current Organic Chemistry Update on the Adverse Effects of Clozapine: Focus on Myocarditis
Current Drug Safety Serendipity of Erythromycin in the Management of Periprosthetic Inflammation
Current Drug Therapy Various Non-Injectable Delivery Systems for the Treatment of Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets Current Strategies and Future Perspective for the Effective Treatment of Diabetic Retinopathy
Current Drug Therapy Influence of Gender on C-Reactive Protein, Fibrinogen, and Erythrocyte Sedimentation Rate in Obstructive Sleep Apnea
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Pandemic of Atopic Diseases - A Lack of Microbial Exposure in Early Infancy?
Current Drug Targets - Infectious Disorders Safety of the Thrombopoiesis-Stimulating Agents for the Treatment of Immune Thrombocytopenia
Current Drug Safety Study of Atomic Force Microscopy in Pharmaceutical and Biopharmaceutical Interactions - A Mini Review
Current Pharmaceutical Analysis The “Classical” Ovalbumin Challenge Model of Asthma in Mice
Current Drug Targets Structure and Expression of Different Serum Amyloid A (SAA) Variants and their Concentration-Dependent Functions During Host Insults
Current Medicinal Chemistry Predicting Drug Efficacy Using Integrative Models for Chronic Respiratory Diseases
Inflammation & Allergy - Drug Targets (Discontinued)